Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

Dr. Marijn Dekkers, Bayer chief executive, 2010-2016 However, before we get into the history of this German pharmaceutical company, it’s a good idea to get your head around the different names ...

Notably, the company warned that 2025 will be weaker ... Sales of glyphosate-based herbicides declined by 19% YoY. Meanwhile, Bayer's Pharmaceutical division has delivered mixed performance.

2025 Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in an interview ...

Berenberg Bank analyst Sebastian Bray maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €22.00. The ...

(Bloomberg) -- Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the company still faces after its $63 billion acquisition of ...

Kepler Capital analyst Christian Faitz maintained a Hold rating on Bayer (0P6S – Research Report) on January 21 and set a price target of ...

Bayer BAYN-0.85%decrease ... a win for the German pharmaceutical and agricultural conglomerate that still faces litigation in the U.S. The group has been hounded by lawsuits since 2018 when ...

Bayer (BAYGn.DE), opens new tab will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in ...